RxDoctor Payments Data

Svetlana Bucchino, MD

Internal Medicine · Muncie, INNPI 1932120847

Payments from drug & device makers

$12,726in general payments, 2019–2025

Across 722 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$996
  • Novo Nordisk$917
  • Amgen$626
  • Pfizer$546
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,61299%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,726 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$73,153
Medicare patients
193
Services billed
768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$77,360
OzempicSemaglutide34$42,320
TrulicityDulaglutide24$37,385
MounjaroTirzepatide27$30,188
JanumetSitagliptin Phos/Metformin Hcl17$19,739
Janumet XrSitagliptin Phos/Metformin Hcl15$17,806
Breo ElliptaFluticasone/Vilanterol29$16,916
FarxigaDapagliflozin Propanediol11$15,999
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$13,250
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,152
JardianceEmpagliflozin13$7,636
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$6,517
SynthroidLevothyroxine Sodium101$5,669
Humulin N KwikpenInsulin Nph Human Isophane13$5,453
Metoprolol Succinate319$5,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$546$78,77279 claims
Lilly USA, LLCTrulicity, Mounjaro$996$67,57351 claims
Novo NordiskOzempic$917$42,32034 claims
MerckJanumet, Janumet Xr$214$37,54632 claims
GSKBreo Ellipta, Anoro Ellipta$508$25,06847 claims
Boehringer IngelheimStiolto Respimat, Jardiance$534$20,88626 claims
AstraZenecaFarxiga$1,391$15,99911 claims
AbbVieSynthroid$1,778$5,669101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →